Compare KKR & Co Inc (KKR) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KKR & Co Inc vs Zimmer Biomet Holdings Inc — how do they compare? KKR & Co Inc trades at $97.25 (market cap $87.07B), while Zimmer Biomet Holdings Inc trades at $90.03 (market cap $17.36B). The key difference: KKR & Co Inc is far larger — about 5× Zimmer Biomet Holdings Inc's market cap, and Zimmer Biomet Holdings Inc pays the higher dividend (1.07%). Which is the better fit depends on your goals.
| KKR | ZBH | |
|---|---|---|
Market Cap | $87.07B | $17.36B |
Sector | Financials | Health |
52-Week High | $152.16 | $107.71 |
52-Week Low | $83.88 | $79.58 |
Enterprise Value | $12.59B | $24.40B |
Dividend Yield | 0.77% | 1.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KKR trades at $96.72, down 4.19% over 24 hours, with a bullish technical signal from moving averages but overbought RSI readings. The company reported Q1 2026 EPS of $1.39, beating estimates, and maintains strong analyst support with 24 buy ratings. Recent developments include a $1.3 billion renewable energy joint venture in South Korea and the acquisition of EDF Power Solutions' North American operations for $4.2 billion, highlighting strategic expansion.
The outlook for KKR is positive, supported by robust deal activity and a favorable analyst consensus price target of $124.33. Key risks include execution of large acquisitions and market sensitivity to interest rate changes. Revenue is projected to grow to $20.4 billion in 2026, with net income margin improving to 14.51%, offering potential upside if operational targets are met.
Zimmer Biomet (ZBH) trades at $89.74, down 1.51% on the day, with a bullish technical signal from moving averages and a consensus price target of $97.67. The company reported revenue of $8.23B in 2025, with net income of $705.10M and a net margin of 8.56%. Recent developments include expansion in Asia Pacific and a planned $1 billion share repurchase program, while Q2 2026 earnings are anticipated on August 5, 2026.
ZBH presents a mixed outlook with strong profitability margins and recent earnings beats offset by declining net income margins and rising debt levels. The stock offers potential upside to analyst targets but faces execution risks in competitive medical markets and macroeconomic pressures on healthcare spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About KKR & Co Inc
KKR is one of the world's largest alternative asset managers, with $490.7 billion in total assets under management, including $384.5 billion in fee-earning AUM, at the end of June 2022. The company has two core segments: asset management (which includes private markets--private equity, credit, infrastructure, energy and real estate--and public markets--primarily credit and hedge/investment fund platforms) and insurance (following the February 2021 purchase of a 61.5% economic stake in Global Atlantic Financial Group, which is engaged in retirement/annuity and life insurance lines as well as reinsurance). On the asset management side, private markets account for 50% of fee-earning AUM and 70% of base management fees, while public markets account for 50% and 30%, respectively.
Read more on KKR →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
